{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:18:04Z","timestamp":1790878684128,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1043134"],"award-info":[{"award-number":["GNT1043134"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1025142"],"award-info":[{"award-number":["GNT1025142"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1073898"],"award-info":[{"award-number":["GNT1073898"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ygyno.2020.07.029","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T08:32:48Z","timestamp":1596702768000},"page":"179-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer"],"prefix":"10.1016","volume":"159","author":[{"given":"Vanessa L.","family":"Beesley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Nagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"DeFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merran","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.07.029_bb0005","series-title":"GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012","author":"IARC and WHO","year":"2012"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/IGC.0b013e3181a3a436","article-title":"Reasons for improved survival from ovarian cancer in New South Wales, Australia, between 1980 and 2003: implication for cancer control","volume":"19","author":"Tracey","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0015","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.6004\/jnccn.2015.0177","article-title":"Making the grade: the impact of low-grade toxicities on patient preference for treatment with novel agents","volume":"13","author":"Castellanos","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejon.2015.10.007","article-title":"Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life","volume":"21","author":"Hwang","year":"2016","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0025","first-page":"1","article-title":"Anxiety and depression in patients with advanced ovarian cancer: a prospective study","author":"Mielcarek","year":"2016","journal-title":"J. Psychosom. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejogrb.2017.07.004","article-title":"Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy","volume":"216","author":"Wen","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0035","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/sj.bjc.6604770","article-title":"A longitudinal investigation of psychological morbidity in patients with ovarian cancer","volume":"99","author":"Gon\u00e7alves","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0040","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1348\/1359107042304542","article-title":"Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study","volume":"9","author":"Hipkins","year":"2004","journal-title":"Br. J. Health Psychol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2407-12-77","article-title":"Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy","volume":"12","author":"Meraner","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejon.2012.10.014","article-title":"Longitudinal assessment of quality of life in ovarian cancer patients","volume":"17","author":"Penar-Zadarko","year":"2013","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2006.01.059","article-title":"Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy","volume":"103","author":"von Gruenigen","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0060","first-page":"1","article-title":"Changes in health-related quality of life among gynecologic cancer survivors during the two years after initial treatment: a longitudinal analysis","author":"Zandbergen","year":"2019","journal-title":"Acta Oncol. (Stockholm, Sweden)"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0065","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/cncr.28188","article-title":"Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis","volume":"119","author":"Clevenger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0070","first-page":"589","article-title":"Quality of life trajectories after diagnosis of gynecologic cancer: a theoretically based approach","volume":"25","author":"Gonzalez","year":"2017","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.12.421","article-title":"A study of symptoms described by ovarian cancer survivors","volume":"125","author":"Stavraka","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0080","first-page":"1421","article-title":"Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials","volume":"19","author":"Greimel","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0085","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/jnci\/djr485","article-title":"Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival","volume":"103","author":"Quinten","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-1611(199703)6:1<1::AID-PON230>3.0.CO;2-C","article-title":"The influence of personal expectations on cancer patients' reports of health-related quality of life","volume":"6","author":"Wan","year":"1997","journal-title":"Psychooncology"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the Hospital Anxiety and Depression Scale. An updated literature review","volume":"52","author":"Bjelland","year":"2002","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jad.2010.01.067","article-title":"Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis","volume":"126","author":"Mitchell","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpsychores.2007.01.009","article-title":"Performance of the Hospital Anxiety and Depression Scale as a screening tool for major depressive disorder in cancer patients","volume":"63","author":"Walker","year":"2007","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0110","first-page":"1899","article-title":"Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis","volume":"19","author":"Vodermaier","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0115","series-title":"Insomnia: Psychological Assessment and Management","author":"Morin","year":"1993"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pon.860","article-title":"Empirical validation of the Insomnia Severity Index in cancer patients","volume":"14","author":"Savard","year":"2005","journal-title":"Psychooncology"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0130","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1200\/JCO.2008.19.1668","article-title":"Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors","volume":"27","author":"Alexander","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0135","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0140","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pon.1428","article-title":"The Queensland Cancer Risk Study: general population norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"18","author":"Janda","year":"2009","journal-title":"Psychooncology"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0145","series-title":"The Active Australia Survey: A Guide and Manual for Implementation, Analysis and Reporting","author":"Australian Institute of Health and Welfare","year":"2003"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0155","series-title":"Advances in Group-Based Trajectory Modeling and an SAS Procedure for Estimating Them. Sociol Methods Res l","first-page":"542","volume":"35","author":"Jones","year":"2007"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0170","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0180","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1200\/JCO.2011.34.6148","article-title":"Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study","volume":"30","author":"Goldstein","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0195","first-page":"42","article-title":"Obesity, physical inactivity and symptoms after ovarian cancer treatment: results from an international internet-based survey","volume":"25","author":"Webber","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0200","first-page":"1205","article-title":"Prevalence, predictors, and correlates of supportive care needs among women 3\u20135 years after a diagnosis of endometrial cancer","volume":"23","author":"Rowlands","year":"2015","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0205","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/pon.3920","article-title":"Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines","volume":"24","author":"Butow","year":"2015","journal-title":"Psychooncology"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S147895151900052X","article-title":"Patterns of, and barriers to supportive care needs assessment and provision for Australian women with gynecological cancer and their caregivers: a mixed-methods study of clinical practice","volume":"18","author":"Beesley","year":"2020","journal-title":"Palliat Support Care"},{"key":"10.1016\/j.ygyno.2020.07.029_bb0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2018.03.052","article-title":"Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study","volume":"149","author":"Bonhof","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.029_bb0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0000000000000592","article-title":"Latest clinical evidence of maintenance therapy in ovarian cancer","volume":"32","author":"Walsh","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:57:38Z","timestamp":1777474658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820336647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0090825820336647"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.029","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}